Dr. Reddy`s Laboratories Accounts Payable

As of the most recent data (June 2026), RDY shows a accounts payable of $37B. That compares with $37B in the prior-year period — up 0.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RDY's accounts payable is now $37B (was $37B) — a 0.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Dr. Reddy`s Laboratories is outperforming or lagging.

Tracking RDY's accounts payable over time shows whether Dr. Reddy`s Laboratories is scaling, shrinking, or reshaping that part of the business. The current reading is $37B That compares with $37B in the prior-year period — up 0.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Dr. Reddy`s Laboratories's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $37B) with ownership activity and broader fundamentals.

Dr. Reddy`s Laboratories's accounts payable is $37B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.